Shares of cardiac diagnostics company Heartbeam Inc. (NASDAQ:BEAT) are trading lower than expected after it opened on the Nasdaq on Nov. 11. The digital health company priced its public offering of 2,750,000 units at $6, but as of midday, shares were trading at $4.56. It’s a disappointing start for the Santa Clara, Calif.-based company, which is developing an ECG telemedicine technology to diagnose cardiovascular patients for ambulatory settings.
Geninus Inc. endured a difficult debut on Korea Exchange’s Kosdaq board, but still raised ₩40 billion (US$33.83 million) through its listing. The 2 million shares on offer tumbled 25.56% at ₩13,400 (US$11.33) at the close of trading on Nov. 8, after Geninus priced them at ₩20,000.
Beijing Airdoc Technology Co. Ltd. raised HK$1.67 billion (US$214.8 million) with its IPO on the Hong Kong Exchange (HKEX) on Nov. 5, falling below its expectations of a $500 million raise. Share prices for the artificial intelligence-based (AI) medical imaging firm were priced at HK$75.10 apiece and dropped 3.5% to HK$72.50.
Shanghai Microport Medbot (Group) Co. Ltd. started trading its shares on the Hong Kong Stock Exchange on Nov. 2, with shares increasing over 6% in the middle of the day. It raised HK$1.56 billion ($201 million) with shares going at HK$43.2 apiece in an initial public offering. The firm plans to use 35% of the proceeds for the development and commercialization of its core product, the laparoscopic surgical robot Toumai.
Medical device maker PHC Holdings Corp. listed on the Tokyo Stock Exchange recently, raising around ¥20 billion (US$175 million). The listing was touted as the biggest IPO in Japan since 2018 but crashed spectacularly. The Tokyo-based company listed on the bourse’s First Section, and saw its shares slide 18% to ¥2,651 per share in their debut on Oct. 14. They were up 1.28% to ¥2,685 at the close of trade on Oct. 21. The 460 million shares that were issued priced at the bottom of a ¥3,250 to ¥3,500 range.
Microtech Medical (Hangzhou) Co. Ltd. raised around HK$1.98 billion (US$254.53 million) via its listing on the Hong Kong stock exchange, becoming the latest in a flood of med-tech companies listing in the city.
Chinese med-tech firms are still flocking to list on the Hong Kong Stock Exchange despite recent disappointing performances. One of these companies is Shanghai Microport Medbot (Group) Co. Ltd., which is looking to raise up to $1 billion in a Hong Kong initial public offering (IPO). Proceeds from the listing will be used for the R&D and commercialization of its core product Toumai Laparoscopic Surgical Robot.
Isoplexis Corp. has debuted on the Nasdaq, pricing its initial public offering of 8.3 million common shares at $15.00 per share. Shares of the proteomics platform developer (NASDAQ:ISO) were trading slightly under at $13 following the listing. The offering is expected to close on Oct. 12, 2021. The Branford, Conn.-based company is aiming to raise $125 million from the public market to accelerate commercialization of its cell analysis platforms. The single-cell proteomics systems are automated, benchtop products designed to reduce therapeutic development timelines.
Broncus Holding Corp.’s shares tumbled more than 20% on its first trading day on Friday, Sept. 24, in Hong Kong. It raised HK$1.55 billion (US$199.1 million) at HK$18.70 a share, the top end of its target range. Nearly half of the proceeds will be used for the R&D and commercialization of its two core interventional pulmonology products: the Intervapor system and the RF Generator + RF Ablation Catheter (RF-II).
PERTH, Australia – On the heels of a A$90 million (US$67.12 million) initial public offering on the Australian Securities Exchange, device company Trajan Group Holdings Ltd. has doubled its share price and is well poised for its next stage of global growth. Trajan makes precision consumable products, devices and solutions that used in analyzing biological samples.